Trogarzo (ibalizumab-uiyk) became the first HIV treatment with a new mechanism of action in more than a decade to gain FDA approval. The CD4-directed post-attachment HIV-1 inhibitor, developed by Theratechnologies Inc., of Montreal, and partner Taimed Biologics Inc., of Taiwan, China, gained the nod in combination with other antiretroviral treatments (ARTs) to treat HIV-1 infection in adults with multidrug-resistant HIV-1 infection who failed an existing ART regimen.